A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors

Part of paid clinical trials in Canton, Ohio.

Sponsor
Turning Point Therapeutics, Inc.
Study ID
NCT05828303
Phase
PHASE1
Status
Withdrawn

Conditions

  • Advanced Solid Tumor
  • Metastatic Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • TPX-0005 — DRUG
    Oral TPX-0005 capsules
  • Metformin Hydrochloride — DRUG
    oral solution
  • Digoxin — DRUG
    oral tablet
  • Rosuvastatin Calcium — DRUG
    oral tablet

Study Details

This is a Phase 1 study to evaluate the potential drug-drug interaction (DDI) effect of repotrectinib on certain drug transporters in patients with advanced cancer.

Key Dates

Start date
Nov 15, 2024
Status verified
Mar 2025
Primary completion
Jul 31, 2025
Completion
Nov 30, 2025

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Repotrectinib (TPX-0005)
    Phase 1 Oral repotrectinib (TPX-0005) + cocktail drugs (metformin hydrochloride, digoxin, rosuvastatin calcium)

Primary Outcome Measure

Area under plasma-concentration time curve [ Time Frame: Within 28 days of first cocktail dose ]

Locations (2)

FacilityCityStateZIPSite coordinators
Gabrail Cancer Research CenterCantonOhio44718-
Local Institution - 2101CantonOhio44718-

Find similar trials in Canton, OH

By research site
Gabrail Cancer Research Center· Canton, OHLocal Institution - 2101· Canton, OH

Related Studies